CAMPRAL Drug Patent Profile

Which patents cover Campral, and when can generic versions of Campral launch?

Campral is a drug marketed by Forest Labs and is included in one NDA.

The generic ingredient in CAMPRAL is acamprosate calcium. Ten suppliers are listed for this compound. Additional details are available on the acamprosate calcium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Campral

A generic version of CAMPRAL was approved as acamprosate calcium by GLENMARK PHARMS LTD on July 16^th, 2013.

Summary for CAMPRAL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CAMPRAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Forest Labs	CAMPRAL	acamprosate calcium	TABLET, DELAYED RELEASE;ORAL	021431-001	Jul 29, 2004		DISCN	Yes	No

Last updated: April 24, 2026

CAMPRAL (acamprosate): Investment scenario and fundamentals analysis

What is CAMPRAL and how is it used commercially?

CAMPRAL is the brand name for acamprosate, an alcohol-use-disorder therapy used to support abstinence after detoxification. In commercial practice, CAMPRAL is positioned for patients who have stopped drinking and seek maintenance of abstinence.

Indication framing (typical label language across markets):

• Used in maintaining abstinence in alcohol dependence, after detoxification.

Product identity

• Active ingredient: acamprosate
• Brand: CAMPRAL
• Drug class: alcohol dependence therapy (non-opioid, non-dopaminergic approach)
• Core value proposition: long-term abstinence maintenance

What does the patent and exclusivity landscape imply for CAMPRAL’s economics?

CAMPRAL’s long market presence means it sits in a post-patent, generic-dominant reality in most major geographies. That structure drives:

• price compression
• substitution by generics
• limited upside from incremental patent-led launches

Practical economic implication for investors: the base case is that CAMPRAL behaves like a mature, pricing-pressure product rather than a late-stage growth asset.

High-level exclusivity posture

• The market is widely served by generic acamprosate products in Europe and other developed markets.
• Revenue opportunity is primarily tied to volume retention, formulary access, and payer contracting rather than exclusivity.

How does CAMPRAL’s demand profile behave?

Demand for alcohol-use-disorder maintenance therapies correlates with three drivers:

1. Prevalence and treatment penetration for alcohol dependence
2. Detox and abstinence pathways that funnel patients into maintenance treatment
3. Payer and clinician behavior in selecting maintenance options

Commercial characteristics

• Treatment is generally chronic/maintenance once initiated.
• Real-world adherence affects outcomes and payer perceptions.
• Competing therapies include other alcohol-use-disorder maintenance agents, but acamprosate’s use case stays anchored to abstinence maintenance post-detox.

Sensitivity to policy and access

• Changes in reimbursement coverage can shift relative uptake.
• Contracting and formulary placement often determine the mix between branded and generic versions.

What are the key competitive dynamics for abstinence maintenance?

CAMPRAL competes in the broader “alcohol dependence maintenance” category against other established drugs and against non-pharmacologic treatment pathways. Competitive pressure is not only therapeutic; it is also economic because generics dominate acamprosate pricing.

Competitive forces

• Generic competition: compresses net price.
• Class competition: other maintenance options and clinician preferences.
• Care pathway competition: detox and counseling referrals influence who reaches maintenance therapy.

Investor takeaway: market share gains tend to come from contracting, adherence support, and channel execution, not from differentiated innovation.

How do fundamentals translate into revenue risk for CAMPRAL?

For a mature, generic-facing product, the fundamental risk stack is stable and predictable:

Revenue drivers

• Volume: number of treated patients and duration of therapy
• Net price: discounts, rebates, and payer terms after generic substitution
• Market access: formulary status and pharmacy benefit structure

Primary risks

• Further price erosion as generic competition increases or as payers tighten preferred drug lists.
• Share loss if another maintenance therapy is preferred in formularies.
• Adherence and discontinuation that reduce persistence and repeat prescriptions.
• Tighter pharmacy benefit controls that shift scripts toward lower-cost SKUs.

What is the likely investment scenario framework?

A realistic investment scenario for CAMPRAL is based on maturity dynamics rather than breakthrough upside.

Base case: mature, low-growth to flat revenue

• Generic acamprosate maintains share
• Net price continues to face gradual downward pressure
• Volume growth is tied to incremental treatment penetration

Downside case: accelerated price pressure and formulary displacement

• Stronger PBM-style contracting compresses pricing further
• Patients shift toward alternative maintenance therapies or non-pharmacologic pathways
• Persistence drops due to substitution pressure and adherence challenges

Upside case: improved access plus stable persistence

• Expanded coverage in select markets
• Better adherence support programs lift persistence
• Brand-to-generic mix stabilizes but net price stabilizes through optimized contracting

What should investors watch in CAMPRAL’s value chain?

For a generic-dominant asset, the most actionable signals are channel and contract metrics.

Commercial KPIs

• Net price trends (store-brand/generic mix)
• Volume growth tied to abstinence maintenance treatment pathways
• Persistence and treatment duration proxies (claims-based duration)
• Formulary tier placement and prior authorization requirements
• PBM preferred status changes that affect script routing

Operational KPIs

• Supply reliability and manufacturing continuity
• Cost of goods trajectory and scale
• Regulatory and quality outcomes that influence market access

How does CAMPRAL fit into the broader alcohol-use-disorder market?

Alcohol-use-disorder treatment is a long-cycle market with a persistent unmet need, but drug economics are shaped by:

• clinician choice and patient selection criteria
• payer coverage restrictions
• adherence and persistence in chronic therapy
• generic erosion in established molecules

CAMPRAL’s commercial role is to support abstinence maintenance after detox. That specific care-positioning can protect some demand even as net prices decline.

What are the investor implications of CAMPRAL’s clinical differentiation?

CAMPRAL’s clinical differentiation in labeling terms supports its niche:

• It is not positioned for relapse induction
• It targets maintenance of abstinence in detoxified patients

In practice, that means it is most likely to be used where clinicians and payers accept a “post-detox abstinence maintenance” workflow. That alignment can support stable demand even in crowded categories.

What does the earnings model look like for CAMPRAL holders?

For branded CAMPRAL revenue holders (or branded generics brand equivalents), the model is often a function of:

• contracted net revenue and pharmacy channel terms
• volume retention against multiple generic competitors
• ongoing cost control for manufacturing and distribution

Key margin drivers:

• generic competition reduces price but does not eliminate margin if volume is protected
• logistics scale matters when price compresses

What are the most material near-term catalysts?

In mature branded/generic markets, catalysts are typically not clinical trial readouts. They are market-structure events:

• formulary wins or losses
• PBM tier changes
• new generic entrants that change competitive intensity
• supply disruptions or quality remediation events
• changes in reimbursement rules for alcohol-use-disorder therapies

How should capital be allocated: CAMPRAL as a defensive vs. optionality position?

CAMPRAL is best treated as a defensive, cash-flow-oriented exposure rather than a high-growth engine, because:

• the base economics follow generic price dynamics
• upside depends on contracting and access rather than patent exclusivity
• category demand is structurally supported by high prevalence, but penetration drives incremental growth

Investment posture

• Defensive: maintain exposure for stable volume and cash generation if net price is protected.
• Optionality: pursue growth only where contract improvements, access expansions, or persistence improvements can be quantified.

---

Key Takeaways

• CAMPRAL (acamprosate) is positioned for maintenance of abstinence after detox in alcohol dependence, which anchors its clinical use-case and supports some demand stability.
• The economics are dominated by generic substitution and pricing pressure, making CAMPRAL a mature, contract-driven asset rather than a patent-led growth story.
• Fundamental risks are predictable: net price erosion, formulary tier pressure, and persistence/discontinuation effects.
• Investment scenarios should be framed around access and contracting (PBM/formulary/supply reliability), not novel clinical breakthroughs.

---

FAQs

1) Is CAMPRAL a first-line therapy for alcohol-use disorder?

CAMPRAL is used in alcohol dependence with a specific workflow: maintenance of abstinence after detoxification, so it functions within maintenance pathways rather than being a universal first-line therapy in all care models.

2) Why does generic competition matter so much for CAMPRAL?

Because acamprosate is established and widely available generically, net prices tend to compress quickly after competitive entry, shifting value toward volume retention and contracting terms.

3) What drives CAMPRAL adoption in real-world settings?

Claims-based adoption tends to follow detox completion and clinician/PBM pathways that support abstinence maintenance prescriptions, plus persistence influenced by tolerability and adherence.

4) What are the biggest operational risks to monitor?

Supply reliability, quality/compliance events, and manufacturing cost inflation matter because revenue is pricing-sensitive and margins depend on operating efficiency.

5) How should CAMPRAL be modeled in an investment case?

Model it as a mature product with revenue sensitivity to net price, volume, and persistence, and treat catalysts as market-structure events (formulary/PBM/supply), not pipeline breakthroughs.

---

References

[1] EMA. Campral (acamprosate) product information. European Medicines Agency.
[2] FDA. Campral (acamprosate) prescribing information (where applicable by US product listing). U.S. Food and Drug Administration.
[3] WHO. Acamprosate for the treatment of alcohol dependence (general therapeutic positioning in alcohol dependence guidance). World Health Organization.